 |
BioWorld-International-2004-07-21
Vernalis, Endo Pact: $400M Potential For Migraine Drug
Vernalis, Endo Pact: $400M Potential For Migraine Drug
For the second time in as many months, London-based Vernalis plc reached across the ocean for a major deal with a U.S. firm, entering this week an agreement worth up to $400 million with pain-drug specialist Endo Pharmaceuticals Inc. focused on the migraine therapy Frova. (BioWorld International)